Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Corgentech Inc.

This article was originally published in Start Up

Executive Summary

Corgentech Inc. aims to avoid the problems that have thwarted viral and liposome-based gene delivery with a pressure-mediated delivery system. Its payload is decoys of transcription factors, the proteins that regulate gene expression. Corgentech's TF decoys are designed to bind with transcription factors, preventing normal DNA from burrowing in and activating its target gene.

You may also be interested in...

ValveXchange Inc.

In heart valve surgery, there have been no home runs yet among the numerous efforts to improve the durability of tissue valves. ValveXchange Inc. has a different solution: improving the way that worn valves are replaced. The start-up is developing a tissue valve with exchangeable leaflets that can be exchanged either percutaneously or via minimally invasive techniques. By focusing on the replacement procedure, ValveXchange aims to make bioprosthetic valves more attractive to the increasingly younger patient population for whom its faster and safer exchange technology will provide a lifetime solution.

Avontec GMBH

Avontec GMBH is a German start up company focused on developing drugs for inflammatory diseases by interfering with transcription factors. Founded in August 2001, the firm has two drugs entering Phase I trials based on its decoy oligonucleotide technology and an agreement with Biotronik GMBH to develop next-generation drug-eluting stents.

Xenerate AB

By marrying gene therapy with medical device technology, Sweden's Xenerate AB believes it can make implantable vascular devices--artificial grafts and stents--capable of endothelialization, thus improving their biocompatibility and reducing the incidence of intimal hyperplasia, restenosis and other adverse effects.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts